for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Incyte Corporation

INCY.O

Latest Trade

65.78USD

Change

-0.85(-1.28%)

Volume

2,573,558

Today's Range

65.21

 - 

66.79

52 Week Range

61.91

 - 

101.47

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
66.63
Open
66.79
Volume
2,573,558
3M AVG Volume
41.41
Today's High
66.79
Today's Low
65.21
52 Week High
101.47
52 Week Low
61.91
Shares Out (MIL)
220.89
Market Cap (MIL)
14,530.18
Forward P/E
18.78
Dividend (Yield %)
--

Next Event

Q4 2021 Incyte Corp Earnings Release

Latest Developments

More

Incyte Reports 2021 Third Quarter Financial Results And Provides Updates On Key Clinical Programs

Incyte Announces The Validation Of The European Marketing Authorization Application For Ruxolitinib Cream In Vitiligo

Incyte Announces Full Results From Phase 3 True-V Program Evaluating Ruxolitinib Cream (Opzelura™) In Patients With Vitiligo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity (IAI), which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs.

Industry

Biotechnology & Drugs

Contact Info

1801 Augustine Cut off

WILMINGTON, DE

19803-4404

United States

+1.302.4986700

https://www.incyte.com/

Executive Leadership

Herve Hoppenot

Chairman of the Board, President, Chief Executive Officer

Christiana Stamoulis

Chief Financial Officer, Executive Vice President

Dashyant Dhanak

Executive Vice President, Chief Scientific Officer

Maria E. Pasquale

Executive Vice President, General Counsel

Jonathan Elliot Dickinson

Executive Vice President, General Manager - Europe

Key Stats

2.15 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.9K

2019

2.2K

2020

2.7K

2021(E)

2.9K
EPS (USD)

2018

1.040

2019

2.830

2020

-0.420

2021(E)

3.503
Price To Earnings (TTM)
27.24
Price To Sales (TTM)
4.99
Price To Book (MRQ)
4.61
Price To Cash Flow (TTM)
24.60
Total Debt To Equity (MRQ)
1.07
LT Debt To Equity (MRQ)
1.00
Return on Investment (TTM)
17.36
Return on Equity (TTM)
14.24

Latest News

Latest News

Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation

Eli Lilly and Co and partner Incyte Corp said on Tuesday additional results from a late-stage study showed their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.

Lilly's COVID-19 drug reduces death risk in patients on mechanical ventilation

Eli Lilly and Co and partner Incyte Corp on Tuesday said additional results from a late-stage study showed that their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation. (Reporting by Manojna Maddipatla in Bengaluru)

U.S. FDA allows Lilly's COVID-19 drug to be taken without remdesivir

The U.S. health regulator expanded the emergency use authorization for Eli Lilly's COVID-19 drug baricitinib, saying it could now be used without taking Gilead's drug remdesivir along with it, Lilly said on Thursday.

Incyte's vitiligo treatment meets main goal in late-stage trial

Incyte Corp said on Monday its ruxolitinib cream to treat pigmentation disorder vitiligo met the main goal in a late-stage study.

Incyte's vitiligo treatment meets main goal in late-stage trial

Incyte Corp said on Monday its cream, ruxolitinib, to treat pigmentation disorder vitiligo met the main goal in a late-stage study.

Incyte to pay $12.6 million to resolve drug charity kickback claims

Biopharmaceutical company Incyte Corp will pay $12.6 million to resolve allegations that it used a charity as a conduit to pay Medicare and Tricare patients kickbacks to use its cancer drug Jakafi, the U.S. Justice Department said on Tuesday.

Eli Lilly's arthritis drug fails to prevent mechanical ventilation in COVID-19 patients

Eli Lilly and Co and Incyte Corp said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized COVID-19 patients under a late-stage study.

Eli Lilly's arthritis drug fails to meet main goal of late-stage COVID-19 study

Rheumatoid arthritis drug baricitinib developed by Eli Lilly and Co and Incyte Corp did not meet the main goal of a late-stage study in hospitalized COVID-19 patients, the drugmakers said on Thursday.

Incyte must face Novartis contract claims in blood drug royalty fight

Delaware drug company Incyte Corp must face a lawsuit by Novartis Pharma AG accusing it of breaching a contract by reducing royalties it paid on a drug used to treat blood disorders the two companies developed together.

BRIEF-Incyte And MorphoSys Announce The Validation Of The European Marketing Authorization Application For Tafasitamab

* INCYTE AND MORPHOSYS ANNOUNCE THE VALIDATION OF THE EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR TAFASITAMAB

BRIEF-Incyte Says Paul Friedman Notified He Will Serve Until 2021 Annual Meeting If Re-Elected As Board Member

* INCYTE - ON MAY 13 PAUL A. FRIEDMAN, M.D. NOTIFIED CO THAT SHOULD HE BE RE-ELECTED AS MEMBER OF BOARD HE WILL SERVE UNTIL 2021 ANNUAL MEETING

BRIEF-Incyte Reports Q1 Loss Per Share Of $3.33

* INCYTE REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS

BRIEF-Incyte Announces Pivotal Reach2 Study Data Published In Nejm Highlight Superior Efficacy Of Ruxolitinib Versus Best Available Therapy In Patients With Acute Graft-Versus-Host Disease

* INCYTE ANNOUNCES PIVOTAL REACH2 STUDY DATA PUBLISHED IN NEJM HIGHLIGHT SUPERIOR EFFICACY OF RUXOLITINIB (JAKAFI®) VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:

BRIEF-FDA Approves First Targeted Treatment For Patients With Cholangiocarcinoma

* FDA APPROVES FIRST TARGETED TREATMENT FOR PATIENTS WITH CHOLANGIOCARCINOMA, A CANCER OF BILE DUCTS

BRIEF-Incyte Announces Initiation Of Phase 3 Ruxcovid Study Evaluating Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm

* INCYTE ANNOUNCES INITIATION OF PHASE 3 RUXCOVID STUDY EVALUATING RUXOLITINIB (JAKAFI®) AS A TREATMENT FOR PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM

BRIEF-Incyte Says Phase 3 Data From True-Ad Program Of Ruxolitinib Cream Support Planned Submission Of NDA To US FDA In 2020

* FIRST PRESENTATION OF PHASE 3 DATA FROM TRUE-AD PROGRAM OF RUXOLITINIB CREAM AT REVOLUTIONIZING ATOPIC DERMATITIS VIRTUAL SYMPOSIUM

RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.

Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19

Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused COVID-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.

BRIEF-Incyte Announces Plans To Initiate A Phase 3 Clinical Trial Of Ruxolitinib (Jakafi®) As A Treatment For Patients With Covid-19 Associated Cytokine Storm

* INCYTE ANNOUNCES PLANS TO INITIATE A PHASE 3 CLINICAL TRIAL OF RUXOLITINIB (JAKAFI®) AS A TREATMENT FOR PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM

BRIEF-Incyte Names New Member To Its Board Of Directors

* INCYTE NAMES NEW MEMBER TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up